BIL vs XBI
SPDR Bloomberg 1-3 Month T-Bill ETF vs SPDR S&P Biotech ETF
BIL$91.44
SPDR Bloomberg 1-3 Month T-Bill ETF
Ultra-short T-Bills, cash-equivalent.
Expense: 0.14%Yield: 3.95%
XBI$133.66
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.34%
Quick take
- • BIL has the lower expense ratio at 0.14% vs 0.35% for XBI.
- • BIL pays a higher dividend yield (3.95%).
Side-by-side metrics
| Metric | BIL | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.14% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.95% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $46.42B | $8.30B |
YTD return | 1.20% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.00 | 1.09 |
P/E ratio | — | — |
Last price | $91.44 | $133.66 |
Inception | — | — |
Issuer | State Street | State Street |
BIL top holdings
Holdings data unavailable for BIL.
XBI top holdings
Top holdings · XBI
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
Sector breakdown · XBI
Financial Services0.2%
Healthcare99.8%
About BIL
BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) is Ultra-short T-Bills, cash-equivalent. Managed by State Street, the fund carries $46.4B in assets under management, an expense ratio of 0.14%, a dividend yield of 3.95%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.